Tumor cells with impaired type I interferon response (IFN-deficient tumor cells)

Tumor cells with impaired type I interferon (IFN) response represent a distinct cellular phenotype rather than a single molecular target. In healthy cells, Type I interferons (IFN-alpha and IFN-beta) bind to the IFNAR receptor, activating the JAK-STAT pathway to induce an antiviral state that inhibits viral replication (Ivashkiv & Donlin, 2014, Nature Reviews Immunology). Many cancers acquire defects in this pathway—such as mutations in JAK1/2, silencing of STING, or loss of IRF7—to evade immune surveillance and promote survival (Xia et al., 2016, Cell Reports). This impairment creates a critical therapeutic window for oncolytic virotherapy, where engineered viruses selectively infect and lyse 'defenseless' tumor cells while being rapidly cleared by the intact IFN response of normal surrounding tissues (Lichty et al., 2014, Nature Reviews Cancer). Beyond direct oncolysis, the destruction of these cells releases tumor-associated antigens and danger signals, potentially converting 'cold' tumors into 'hot' tumors susceptible to checkpoint inhibitors. This target state is currently exploited by FDA-approved therapies like Talimogene laherparepvec and various viral platforms in clinical development.

Other names

Type I interferon-deficient cancer cellsIFN-nonresponsive tumor cellsAntiviral-deficient malignant cellsIFN-pathway defective tumors

Selective viral replication within cells lacking functional Type I IFN signaling, leading to direct oncolysis and induction of systemic anti-tumor immunity (Stojdl et al., 2003, Cancer Cell).